Submissions

Author Guidelines

Author Submission Guidelines – ASIDE Oncology

Submission Invitation

Authors are invited to submit their work to ASIDE Oncology. All submissions will be evaluated by an editor to determine if they align with the aims and scope of the journal. Submissions deemed a good fit will be sent for peer review before a final decision is made regarding acceptance or rejection.

Before submitting, authors are responsible for securing permission for all material included in their manuscript, such as images, documents, and datasets. All listed authors must consent to be identified as authors. Where relevant, research involving humans or animals must have received appropriate ethics committee approval, following the legal requirements of the study’s country.

Editors may desk-reject submissions that do not meet minimum quality standards. Please ensure your study design and research argument are well-structured and clearly articulated. The title should be concise, and the abstract must stand alone. Following these standards increases the likelihood that reviewers will agree to assess your work. When you are confident your submission meets these requirements, please follow the checklist below to prepare your manuscript.

1. REQUIRED FILES

Each submission to ASIDE Oncology must include:

• Title Page File (Word document)

• Main Manuscript File (blinded)

• Tables File(s)

• Figures (PowerPoint format)

• Manuscript Highlights File

• ICMJE Disclosure of Interest form — one completed PDF per author

• Required Documentation (depending on study type)

2. TITLE PAGE FILE SPECIFICATIONS

1. Manuscript Title

   • Clear, concise, and reflective of oncology content

   • Avoid abbreviations unless standard in oncology

2. Author Information

   • Full names with academic degrees

   • Institutional affiliations and full addresses

   • Email addresses for all authors

   • ORCID identifier (mandatory for corresponding author, optional for others)

3. Corresponding Author Details

   • Complete contact information, including institutional address, telephone, email, and ORCID ID (mandatory)

3. MANUSCRIPT TEMPLATES 

Please prepare your submission using the ASIDE templates: HERE

MAIN MANUSCRIPT STRUCTURE

1. Blinding Requirements

   • Remove all author identifiers

   • Eliminate self-referential statements

2. Required Sections

   • Abstract (max 300 words): Structured (Background, Methods, Results, Conclusions). No undefined abbreviations or citations.

   • Keywords: 3-6 keywords

   • Main Text: Introduction, Methods, Results, Discussion, Conclusions

   • Declarations panel on the submission form (required). When you submit, you will see a Declarations step at For the Editors. It offers standard wording for each statement below that you can select and then edit. The following statements are required and the form will not let you submit until each is answered: Conflicts of Interest, Funding Sources, Ethics Approval/IRB Statement, Informed Consent Statement, Data Availability Statement, Use of Generative AI, and Authors Contribution Statement. Acknowledgements are optional. Nothing is pre-filled: every statement is your own declaration. Where a standard wording contains a slot in square brackets, such as [FULL NAME OF COMMITTEE], please fill it in; an unfilled slot publishes exactly as written. Please also keep the Declarations section in your manuscript as described here.

     ICMJE Disclosure of Interest forms (required). Every listed author must personally complete the official ICMJE Disclosure of Interest form. The corresponding author uploads one completed form per author at submission, using the file component Disclosure of Interest (ICMJE form), named ICMJE - Surname Initials.pdf. A submission with a missing form for any author will be returned. We also encourage every author to connect an ORCID iD; the journal will email each author an ORCID verification request on acceptance.

     Declarations:

     • Conflicts of Interest — if there are none, write: “The authors declare that they have no competing interests.”

     • Ethics Approval/IRB Statement — give the full name of the approving committee and the approval number. If approval was waived or not required, say who determined that and why.

     • Informed Consent Statement — if no identifiable individual patient data are reported, write: “Not applicable. No identifiable individual patient data are reported.”

     • Funding Sources — name each funder and grant number. If there was no funding, write: “The authors received no specific funding for this work.”

     • Acknowledgements — optional. Omit this heading entirely if there is nothing to acknowledge.

     • Data Availability Statement (explain if not applicable)

     • Large-Language Model (LLM) – Generative AI Use Statement — if no AI tools were used, write: “The authors declare that no generative artificial intelligence tools were used in the preparation of this manuscript.”
       Example: “We have employed an advanced Large Language Model (LLM) to enhance and refine the English-language writing. This process focused solely on improving the text’s clarity and style, without generating or adding any new information to the content.”

     • Authors’ Contribution Statement (mandatory, using CRediT taxonomy; e.g., Conceptualization, Methodology, Software, etc.)

   • References: Vancouver style, all references must include DOI and PMCID/PMID if available, or URL if not. List references in the order they appear in the text.

4. FIGURES AND TABLES SPECIFICATIONS

1. Figures

   • Format: PowerPoint files only (required)

   • Dimensions: 1200x1200 pixels minimum, 3000x3000 pixels maximum

   • Resolution: Minimum 300 dpi

   • One figure per slide

   • Legend: Place below the figure; define abbreviations, explain symbols/markers, include scale bars (if applicable), use color only with scientific justification

2. Tables

   • Format: Word document

   • Structure: Clear, descriptive titles, no vertical lines, consistent formatting

   • Legend: Place below the table; define abbreviations, explain symbols/statistics, add notes if necessary

5. REQUIRED DOCUMENTATION BY MANUSCRIPT TYPE

• Editorial, Review, Frontier, Field of Vision, Minireview, Letter to The Editor, Correction, Retraction Note: None required.

• Basic Science / Pre-Clinical Study:

  • Clinical Trial Registration (recommended)

  • Institutional Animal Care and Use Committee statement (for animal studies)

  • ARRIVE Guidelines (for animal research)

• Retrospective Study, Clinical Practice Study:

  • Clinical Trial Registration

  • Signed Informed Consent (for human research)

• Case Control, Observational, Retrospective Cohort Study:

  • Clinical Trial Registration

  • Signed Informed Consent

  • STROBE Statement

• Clinical Trial/Prospective/Randomized Controlled Trial:

  • Clinical Trial Registration

  • Signed Informed Consent

  • CONSORT 2010 Statement

• Systematic Review, Meta-Analysis:

  • PRISMA 2020 Checklist

• Case Report:

  • Signed Consent for Treatment

  • CARE Checklist

6. REVISION REQUIREMENTS

• Revised Manuscript Versions:

  • Version 1: Changes highlighted in yellow

  • Version 2: Clean copy

• Response to Reviewers:

  • Point-by-point, with page/line numbers for changes and justification for declined suggestions

COMPLIANCE STATEMENT

Manuscripts not conforming to these specifications will be returned without review. Authors must verify compliance with all requirements before submission. The editorial office reserves the right to reject manuscripts not meeting these standards at any stage.

Author Charges Policy

• No Charges: ASIDE Oncology does not impose any fees at any stage of the manuscript process, including:

  • Submission fees

  • Editorial processing charges

  • Article processing charges (APCs)

  • Page or color charges

• Fee Waivers: Not applicable, as there are no charges.

• Withdrawal Charges: No withdrawal fees. Authors are encouraged to submit only when ready for review to avoid unnecessary processing.

Plagiarism Policy

• Commitment to Originality: All submissions are screened for plagiarism to uphold the highest standards of publication ethics and integrity.

• Similarity Screening: All submissions undergo similarity screening before peer review. Authors are encouraged to check their work for originality before submission. Screening output is interpreted by the editorial team alongside the manuscript itself; no single numerical score determines the outcome.

• Where screening identifies overlapping text, the editorial team assesses its extent, location and significance. Manuscripts may be returned to the authors for revision, or rejected, where the overlap represents unattributed reuse of another work.

ASIDE Crossmark Policy

• Permanency of Content: All ASIDE Oncology articles receive a DOI and are permanently published, regardless of peer review outcome.

• Archiving: All content is permanently archived, including articles not yet peer-reviewed. Peer-reviewed articles are archived in databases.

• Content Updates: The Crossmark logo on each article links to its current status and the latest version, providing additional information as needed.

Correction to an Article

• Corrections (Errata) are published to alert readers to post-publication errors.

Retraction

• Articles may be retracted for reasons including honest error, research misconduct, duplicate publication, fraudulent data, plagiarism, or unethical research.

• Retraction notices will clearly state the reason, who initiated the retraction, and will be linked to the original article (which will be marked as retracted).

• Articles are retracted only at the author’s request or by the publisher following investigation.

• Content may be removed only for legal reasons (e.g., defamatory or court-ordered removal), with bibliographic details and explanation retained.

Editorial Note

• If there is an unresolved issue or ongoing investigation, an Editorial Note may be posted to alert readers.

For more details, please contact the editorial office at contact@ASIDEjournals.com.